

1 **[TITLE PAGE]**

2 **Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted**
3 **Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older**
4 **Adults: A Randomized Controlled Trial**

5 Vivek Shinde, MD¹: vshinde@novavax.com

6 Iksung Cho, MS¹: icho@novavax.com

7 Joyce S. Plested, PhD¹: jplested@novavax.com

8 Sapeckshita Agrawal, PhD²: sapeck.srivastava@gmail.com

9 Jamie Fiske, MS¹: jfiske@novavax.com

10 Rongman Cai, PhD³: rongmancai.m@gmail.com

11 Haixia Zhou, PhD¹: hzhou@novavax.com

12 Xuan Pham, PhD⁴: xuanami9@gmail.com

13 Mingzhu Zhu, PhD¹: mzhu@novavax.com

14 Shane Cloney-Clark, BS¹: wcloneyclark@novavax.com

15 Nan Wang¹, MS: wongnan@hotmail.com

16 Bin Zhou, PhD¹: bzhou@novavax.com

17 Maggie Lewis, MS¹: mlewis@novavax.com

18 Patty Price-Abbott, RN¹: pprice-abbott@novavax.com

19 Nita Patel, MS¹: npatel@novavax.com

20 Michael J Massare, PhD¹: mmassare@novavax.com

21 Gale Smith, PhD¹: gsmith@novavax.com

22 Cheryl Keech, MD¹: ckeech@novavax.com

23 Louis Fries, MD¹: lfries@Novavax.com

24 Gregory M Glenn, MD¹: gglenn@novavax.com

25

26 ¹Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878

27 ²Previously with Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878. Currently with
28 Assembly Biosciences, 331 Oyster Point Blvd, South San Francisco, CA 94080

29 ³Previously with Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878. Currently with
30 Parexel, 1 Federal St, Billerica, MA 01821

31 ⁴Previously with Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878. Currently with
32 AstraZeneca Pharmaceuticals, One MedImmune Way, Gaithersburg, MD 20878.

33 **Corresponding Author:** Vivek Shinde, MD, MPH, Novavax Inc., 21 Firstfield Road,
34 Gaithersburg, MD 20878 (vshinde@novavax.com)

35 **Clinicaltrials.gov Registration:** NCT04120194

36 **Funding/Support:** This trial was funded by Novavax, Inc.

37 **Role of the Funder/Supporter:** The Sponsor funded the trial and was responsible for the
38 design and conduct of the study; collection, management, analysis, and interpretation of the
39 data; preparation, review, and approval of the manuscript; and decision to submit the
40 manuscript for publication.

41 **Manuscript word count:** 3012 words

42

43

44 **ABSTRACT**

45 **Background:** Improved seasonal influenza vaccines for older adults are urgently needed, which
46 can induce broadly cross-reactive antibodies and enhanced T-cell responses, particularly
47 against A(H3N2) viruses, while avoiding egg-adaptive antigenic changes.

48 **Methods:** We randomized 2654 clinically-stable, community-dwelling adults ≥ 65 years of age
49 1:1 to receive a single intramuscular dose of either Matrix-M-adjuvanted quadrivalent
50 nanoparticle influenza vaccine (qNIV) or a licensed inactivated influenza vaccine (IIV4) in this
51 randomized, observer-blinded, active-comparator controlled trial conducted during the 2019-
52 2020 influenza season. The primary objectives were to demonstrate the non-inferior
53 immunogenicity of qNIV relative to IIV4 against 4 vaccine-homologous strains, based on Day 28
54 hemagglutination-inhibiting (HAI) antibody responses, described as geometric mean titers and
55 seroconversion rate difference between treatment groups, and to describe the safety of qNIV.
56 Cell-mediated immune (CMI) responses were measured by intracellular cytokine analysis.

57 **Findings:** qNIV demonstrated immunologic non-inferiority to IIV4 against 4 vaccine-
58 homologous strains as assessed by egg-based HAI antibody responses. Corresponding wild-
59 type HAI antibody responses by qNIV were significantly higher than IIV4 against all 4 vaccine-
60 homologous strains (22-66% increased) and against 6 heterologous A(H3N2) strains (34-46%
61 increased), representing multiple genetically and/or antigenically distinct clades/subclades (all p-
62 values < 0.001). qNIV induced 3.1- to 3.9- and 4.0- to 4.9-fold increases in various
63 polyfunctional phenotypes of antigen-specific effector CD4+ T-cells against A(H3N2) and
64 B/Victoria strains at Day 7 post-vaccination, respectively, while corresponding fold-rises induced
65 by IIV4 at Day 7 were 1.3-1.4 and 1.7-2.0; representing a 126-189% improvement in CMI
66 responses for qNIV (all p-values < 0.001). Local reactogenicity, primarily mild to moderate and
67 transient pain, was higher in the qNIV group.

68 **Interpretation:** qNIV was well tolerated and produced a qualitatively and quantitatively
69 enhanced humoral and cellular immune response in older adults. These enhancements may be
70 critical to improving the effectiveness of currently licensed influenza vaccines.

71 **Funding:** Novavax.

72 INTRODUCTION

73 The substantial health and economic burden of influenza in older adults has remained largely
74 unabated despite vaccination coverage rates in excess of 60% over the past decade, due in
75 part to the suboptimal vaccine effectiveness (VE) of existing influenza vaccines.¹⁻⁴ During two
76 recent US influenza seasons, VE among older adults was reported to range between 10% and
77 13% for the A(H3N2) component of the vaccine—a problematic observation, because
78 historically, A(H3N2) viruses have circulated more frequently, accounted for the majority of
79 influenza morbidity and mortality, evolved genetically and antigenically the most rapidly,
80 necessitating frequent vaccine strain updates, and, taken together, represented the “weak link”
81 in influenza vaccine performance.⁵⁻¹⁰

82 Several challenges have converged over the past decade to degrade the effectiveness of
83 traditional inactivated influenza vaccines (IIVs) in older adults.^{7,8,11} A long-standing challenge
84 has been the induction of narrow, strain-specific antibody responses, resulting in increasing
85 vulnerability to antigenic drift arising from an expanding diversity of circulating viruses.¹¹ A
86 second, recently recognized challenge has been the introduction of deleterious egg-adaptive
87 antigenic changes in vaccine virus hemagglutinins (HAs), due to the near universal reliance on
88 traditional egg-based vaccine production methods.¹²⁻¹⁶ A third challenge has been the limited
89 induction of T-cell immunity by existing approaches, particularly among older adults.¹⁷⁻¹⁹

90 These limitations, coupled with specific characteristics of the older adult population—age-
91 related immunosenescence, multi-morbidity, and concomitant increases in physiological frailty—
92 have prompted the development of “enhanced” influenza vaccines, which have included a high-
93 dose IIV (IIV-HD), a MF-59-adjuvanted IIV (aIIV), and a recombinant HA influenza vaccine
94 (RIV).^{17,20-25} Notwithstanding, critical gaps in vaccine performance remain. IIV-HD contains a
95 four-fold higher content of influenza antigens, while aIIV contains an oil-in-water emulsion
96 adjuvant. Both have demonstrated improvements in hemagglutination-inhibiting (HAI) antibody

97 responses, and in VE, compared to traditional IIVs.^{23,24,26-31} However, with both IIV-HD and aIIV,
98 the problems of suboptimal induction of T-cell responses and introduction of egg-adaptive
99 antigenic changes remain unaddressed; further, with IIV-HD, the improvements in efficacy have
100 lacked breadth of cross-protection against drift variants.^{18,19,24,27,32-35} Finally, RIV, containing a
101 three-fold higher content of influenza antigens, avoids the problems of egg-adaptive antigenic
102 changes, and has shown improved relative VE compared to a traditional IIV during a season
103 characterized by circulation of antigenically drift A(H3N2), but, to date, has not demonstrated
104 substantial induction of T-cell responses.^{18,25,36}

105 To address multiple gaps limiting the performance of existing enhanced influenza vaccines, we
106 developed a novel recombinant, *Spodoptera frugiperda* (Sf9) insect cell/baculovirus system
107 derived, quadrivalent HA nanoparticle influenza vaccine (qNIV), formulated with a saponin-
108 based adjuvant, Matrix-M.^{37,38} Through previous phase 1 and 2 trials, we demonstrated that
109 qNIV induced broadly cross-reactive HAI antibodies as compared to IIV-HD, and increased
110 antigen-specific polyfunctional CD4+ T-cell responses as compared to IIV-HD *and* RIV.^{37,39,40} To
111 advance the candidate qNIV towards licensure via the US Food and Drug Administration's
112 accelerated approval pathway, we conducted a pivotal phase 3 trial to test the hypothesis that
113 qNIV would be immunologically non-inferior to a licensed, standard-dose, quadrivalent
114 inactivated influenza vaccine (IIV4) in older adults.

115 **METHODS**

116 **Study Design**

117 This was a phase 3, randomized, observer-blinded, active-controlled trial at 19 US clinical sites,
118 conducted in advance of the 2019-2020 influenza season.

119 **Participants**

120 Clinically stable adults aged ≥ 65 years who had not received an influenza vaccine within six
121 months preceding the trial and had no known allergies or serious reactions to influenza vaccines
122 were enrolled. Stable health was defined by absence of: a) changes in medical therapy within
123 the preceding one month due to treatment failure or toxicity, b) medical events qualifying as
124 serious adverse events (SAEs) within the preceding two months, and c) life-limiting diagnoses.

125 **Randomization and Masking**

126 A randomization sequence was generated using an interactive web response system to allocate
127 participants 1:1 to receive a single intramuscular dose of qNIV or IIV4. Treatment assignments
128 were known only to the responsible unblinded vaccine administrators, who did not perform any
129 trial assessments post-dosing. Participants and other site staff remained blinded for the duration
130 of the trial. Stratification was by age (65 to <75 years; ≥ 75 years) and receipt of prior-year
131 influenza vaccine (Supplement 1.1-1.3). This report summarizes the results of a pre-specified
132 interim analysis, which was conducted upon completion of Day 28 visits for all participants.
133 Blinded safety follow-up through one year is ongoing. The trial was approved by the Advarra
134 Institutional Review Board (Columbia, Maryland, USA). All participants provided informed
135 consent and were free to withdraw at any time from the trial (Supplement 1.4).

136 **Procedures**

137 **Vaccines**

138 qNIV contained 60 μg recombinant hemagglutinin (HA) per strain for the four influenza strains
139 recommended by the World Health Organization (WHO) for inclusion in the 2019-2020 Northern
140 Hemisphere seasonal influenza vaccine, and was formulated with 75 μg of Matrix-M adjuvant.
141 IIV4 contained 15 μg HA per recommended strain (Supplement 1.5).

142 **Objectives**

143 The primary objectives were to a) demonstrate the non-inferior immunogenicity of qNIV as
144 compared to IIV4, in terms of HAI antibody responses assayed with classical egg-propagated
145 virus reagents (hereafter “egg-based HAI”) to the four vaccine-homologous strains at Day 28
146 post-vaccination; and b) describe the safety of qNIV compared to IIV4. The secondary objective
147 was to describe HAI antibody responses assayed with wild-type sequence HA virus-like particle
148 (VLP) reagents (hereafter “wt-HAI”) against the four vaccine-homologous strains; multiple
149 genetically and or antigenically distinct heterologous A(H3N2) strains; and a heterologous,
150 antigenically distinct B strain (Figure S1). The pre-specified exploratory objective was to
151 describe the quality and amplitude of cell-mediated immune (CMI) responses of qNIV, as
152 measured by flow cytometry with intracellular cytokine staining analysis (ICCS) (Supplement
153 1.6).

154 **Outcomes**

155 **Safety**

156 Safety was described in terms of solicited local and systemic adverse events (AEs) within seven
157 days of vaccination, reported by participants in diaries, and as unsolicited AEs, including SAEs,
158 medically attended adverse events (MAEs), and other significant new medical conditions
159 (SNMCs) through Day 28 of the trial.

160 **Immunogenicity**

161 Blood samples for antibody response assessments were collected on Day 0 pre-vaccination and
162 Day 28 post-vaccination. Peripheral blood samples for isolation of mononuclear cells (PBMCs)
163 for CMI assessments were collected from a subset of 140 participants (~70 per treatment
164 group) at two pre-designated sites on Day 0 pre-vaccination and Day 7 post-vaccination
165 (Supplement 1.7).

166 **Statistical Analysis**

167 The per protocol (PP) population was the primary population for immunogenicity, and included
168 randomized participants who received the assigned dose of the test article according to the
169 protocol, had HAI serology results at Day 0 and Day 28, and had no major protocol deviations
170 (Figure 1). HAI antibody responses were summarized as geometric mean titers (GMTs); within
171 group geometric mean fold-rises from pre- to post-vaccination at Day 28 ($GMFR_{post/pre}$); the
172 baseline-adjusted ratio of GMTs between qNIV and IIV4 at Day 28 ($GMTR_{qNIV/IIV4}$);
173 seroconversion rates (SCRs); and SCR difference ($SCR_{qNIV} - SCR_{IIV4}$) (Tables 3, 4Supplement
174 1.8). The immunologic non-inferiority of qNIV to IIV4 was demonstrated if the *lower bound* of the
175 two-sided 95% CI of the Day 28 post-vaccination $GMTR_{qNIV/IIV4}$ was ≥ 0.67 , and if the *lower*
176 *bound* of the two-sided 95% CI of SCR difference at Day 28 ($SCR_{qNIV} - SCR_{IIV4}$) was $\geq -10\%$, for
177 all four homologous strains.

178 CD4+ T-cells responding to *in vitro* stimulation with homologous influenza HA antigens
179 (A/Kansas [H3N2] or B/Maryland [Victoria]) by expressing interferon gamma (IFN- γ) either as a
180 single cytokine marker or as polyfunctional arrays of greater than or equal to two, three, or four
181 cytokines/activation markers consisting of combinations of the following: IFN- γ , tumor necrosis
182 factor alpha (TNF- α), interleukin-2 (IL-2), or CD40L, which were reported as median counts and
183 geometric mean counts (GMCs) per million cells. Within-group geometric mean fold-rises in
184 counts from pre- to post-vaccination at Day 7 ($GMFR_{post/pre}$) and baseline-adjusted ratio of
185 GMCs between qNIV and IIV4 at Day 7 ($GMTR_{qNIV/IIV4}$) were calculated (Table S1).

186 The sample size of 1325 per treatment group (total 2650) was selected to achieve an overall
187 power of 90% to demonstrate non-inferiority for all four homologous strains on both GMTR and
188 SCR difference success criteria at a significance level of 0.025, while assuming 10% attrition
189 (Supplement 1.8).

190 **Role of Funding Source**

191 The funder, Novavax, was the trial sponsor.

192 **RESULTS**

193 **Participants**

194 A total of 2654 participants were enrolled and randomized from 14-25 October, 2019, of whom
195 2652 received treatment on Day 0 (1333 in qNIV group and 1319 in IIV4 group) and constituted
196 the safety population (Figure 1). The immunogenicity PP population consisted of 2566
197 participants. Similar percentages of participants from both treatment groups (99.3% qNIV and
198 99.8% IIV4) completed follow-up through Day 28. Of the 11 participants who discontinued, only
199 one (0.1%) qNIV and two (0.2%) IIV4 participants discontinued due to an AE (Figure 1). The
200 median participant age ranged from 71 to 72 years. The majority of participants were females
201 (59.4% in qNIV; 64% in IIV4) and white (91%). Approximately 84% of participants in both groups
202 received an influenza vaccine during the prior influenza season (2018-2019) (Table 1).

203 **Safety**

204 Approximately 49.4% and 41.8% of qNIV and IIV4 participants, respectively, experienced at
205 least one treatment-emergent adverse event (TEAE). The differences in overall TEAEs were
206 driven primarily by differences in solicited AEs during the seven days following vaccination and,
207 in particular, mild to moderate and transient injection site pain.

208 Overall solicited AEs were reported by 41.3% of qNIV and 31.8% of IIV4 participants (Table 2).
209 Local solicited AEs followed a similar pattern (27.0% vs 18.4%), led primarily by injection site
210 pain (25.6% vs 16.1%) and swelling (6.3% vs. 3.1%) (Table S3). Severe local solicited events
211 were infrequent in both groups (0.6% vs 0.2%). Proportions of participants with systemic
212 solicited AEs were comparable (27.7% vs 22.1%). The most common systemic solicited AEs
213 were muscle pain (12.5% vs 8.0%), headache (10.7% vs 7.9%), and fatigue (9.4% vs 7.1%)
214 (Table S3). Severe systemic solicited AEs were infrequent in both groups (1.1% vs 0.8%).

215 Similar proportions of participants experienced unsolicited AEs (18.6% vs 18.3%) and MAEs
216 (7.4% vs. 7.9%) with diagnoses spanning common intercurrent illnesses for this age group, with
217 no apparent clustering of specific AEs by treatment group. SAEs were infrequent and occurred
218 in comparable proportions per group (0.8% vs 0.4%) (Table 2). One death occurred per
219 treatment group; neither was considered related to treatment by trial investigators.

220 **Immunogenicity**

221 **HAI antibody responses**

222 The primary objective of the trial was met with qNIV demonstrating immunologic non-inferiority
223 to IIV4 against four vaccine-homologous strains based on the pre-specified GMTR and SCR
224 difference success criteria, as assessed by egg-based HAI antibody responses, and qNIV
225 showed statistically improved responses for three of four vaccine-homologous strains (Table 3).

226 When HAI antibody responses were assessed in a more biologically-relevant wt-HAI assay
227 format, which features known wild-type HA sequences and human, rather than avian, glycans
228 as HA receptors in the agglutination reaction, the relative improvements in antibody responses
229 were further accentuated in favor of qNIV. Specifically, Day 28 post-vaccination GMFRs for the
230 four vaccine-homologous strains showed 2.1- to 5.6-fold increases in titers for qNIV, as
231 compared to 1.6 -to 3.4-fold increases for IIV4. The Day 28 GMTRs showed statistically
232 significant improvements of 24%-66% in post-vaccination wt-HAI antibody responses for qNIV
233 as compared to IIV4 against all four vaccine-homologous strains (all p-values <0.001);
234 corresponding Day 28 SCR differences showed increases of 11.4%-20.4% (all p-values <0.001)
235 (Table 3).

236 Next, we assessed the breadth of cross-reactive antibody responses (Figure S1). GMTRs of
237 qNIV versus IIV4 showed statistically significant improvements of 34%-46% in post-vaccination

238 wt-HAI antibody responses against six heterologous A(H3N2) strains, and a 23% improvement
239 against a heterologous B-Victoria lineage strain (all p-values <0.001) (Table 4).

240 **Cell-mediated immune responses**

241 Baseline and post-vaccination CMI responses assessed across *effector* (memory) and *total*
242 CD4+ T-cells producing single or multiple cytokines/activation markers following *in vitro*
243 stimulation with influenza HAs are shown in Figures 2a-c, S2- S9, and Table S1. Pre-
244 vaccination baselines were comparable in both groups. At Day 7 post-vaccination, a
245 substantially greater induction of IFN- γ and polyfunctional responses was evident in qNIV
246 versus IIV4 recipients, with GMFRs for qNIV stimulated with A/Kansas HA reaching 3.1-, 3.4-,
247 3.9-, and 4.6-fold increases for double-, triple-, quadruple-, and IFN- γ -cytokine producing
248 *effector* CD4+ T-cells, respectively (all p-values <0.001). This was in contrast to notably lower
249 Day 7 GMFRs observed for IIV4, ie, 1.3-, 1.3-, 1.4-, and 1.6-fold increase, respectively, for the
250 same parameters (Figure 2c, Table S1). Corresponding GMFRs for B/Maryland followed a
251 similar pattern (Figure 2c, Table S1). Between-group differences at Day 7, as measured by
252 $GMCR_{qNIV/IIV4}$, showed 141-195% relative increases in induction of double-, triple-, quadruple-,
253 or IFN- γ -cytokine producing *effector* CD4+ T-cells following A/Kansas HA stimulation (all p-
254 values <0.001); and 126-155% relative increases in corresponding responses after stimulation
255 with B/Maryland HA (all p-values <0.001) (Table S1). Vaccine-induced responses measured
256 among *total* CD4+ T-cells produced a pattern similar to *effector* CD4+ T-cell population for all
257 cytokine parameters assessed (Table S1; Figures S6-S9).

258 Two overall patterns of responses were consistent across *total* and *effector* CD4+ T-cell
259 subsets, cytokine parameters, and strains. First, as described previously, qNIV induced
260 substantially higher post-vaccination polyfunctional CD4+ T-cell responses than IIV4 (Figures
261 2a-b, S2-S3, S6-S7). Second, as evident on the reverse cumulative distribution (RCD) plots, the
262 entire distribution of pre-vaccination baseline responses were substantially and symmetrically

263 shifted to the right following vaccination with qNIV. In contrast, in the IIV4 group, the
264 distributions of pre-vaccination responses were more modestly and asymmetrically shifted
265 following vaccination (Figures 2a-b, S4-S5, S8-S9). Specifically, those participants with low
266 baseline Day 0 responses in the IIV4 group remained CMI “non-responders” to A/Kansas
267 following vaccination; whereas, with qNIV, all participants, including those with the lowest
268 baseline responses, achieved substantial induction of CMI responses following vaccination
269 (Figures S4-S5, S8-S9, S11).

270 **DISCUSSION**

271 In this pivotal phase 3 trial, we report four important findings. First, qNIV demonstrated non-
272 inferiority to IIV4, based on HAI assays using conventional egg-derived reagents against the
273 four homologous strains contained in both vaccines. Second, when HAI antibody responses
274 were assayed with human indicator red blood cells and agglutinating reagents, which display
275 HA proteins with wild-type sequences, a more biologically relevant assay format, qNIV induced
276 qualitatively and quantitatively greater HAI antibody responses relative to IIV4, against both
277 vaccine homologous strains, achieving 24-66% improvements in GMTs at Day 28, as well as
278 against a wide array of antigenically distinct A(H3N2) strains, which showed improvements of
279 34-46% over IIV4 in Day 28 GMTs. Third, qNIV significantly outperformed IIV4 in the induction
280 of various influenza HA antigen-specific polyfunctional effector (memory) and total CD4+ T-cell
281 phenotypes, achieving increases of 126%-189% over IIV4 at Day 7 post-vaccination. Finally,
282 qNIV was well tolerated, with a safety profile generally comparable to IIV4, except for a higher
283 incidence of transient mild to moderate injection site pain (25.4%), which is comparable to or
284 less than rates published for aIIV4 (24.7%) and IIV3-HD (35.3%), respectively.^{41,42}

285 The recombinant wild-type HA antigen in qNIV is insect cell derived and forms via self-assembly
286 of full-length HA trimers, three to seven of which further organize into a 20-40 nm sized protein-
287 detergent nanoparticle. This format may enhance antigen recognition by increasing B- and T-

288 cell access to conserved HA epitopes, thereby improving the quality and breadth of the antibody
289 response.^{37,38} This was evidenced by immunization of ferrets and humans (in phase 1) with
290 either tNIV or IIV3-HD, wherein we detected the presence of post-vaccination antibodies in tNIV
291 treated groups that could compete with known broadly neutralizing A(H3N2)-specific
292 monoclonal antibodies for binding to conserved HA head and stem epitopes in a manner that
293 IIV3-HD did not, suggesting that tNIV could induce a broadly cross-reactive antibody response,
294 while IIV-HD, by contrast, induced an antigenically constrained strain-specific response.^{38,39}

295 Formulation of qNIV with Matrix-M adjuvant—which has been shown to enhance antigen
296 presentation, expand the recognized antibody epitope repertoire, enhance neutralizing and
297 cross-neutralizing antibody responses, and improve induction of potent CD4+ and CD8+T-cell
298 responses for a variety of vaccines antigens under development—is central to improved
299 induction of antibody and cellular responses against influenza HA antigens.⁴³⁻⁵⁰ In a previous
300 phase 2 trial of qNIV, we showed an adjuvant effect when comparing Matrix-M-adjuvanted qNIV
301 to unadjuvanted qNIV, demonstrating statistically significant increases in both HAI antibody (15-
302 29% greater) and polyfunctional CD4+ T-cell (11.1-13.6 fold higher) responses.⁴⁰ In the present
303 trial, we again demonstrated marked induction of cell-mediated immune responses in a manner,
304 to our knowledge, not previously reported.^{18,19} A recent randomized controlled trial in older
305 adults from Hong Kong compared the immunogenicity of three enhanced vaccines—IIV-3 HD,
306 aIIV, and RIV—against IIV4, and showed Day 7 post-vaccination GMFRs of IFN- γ -producing
307 CD4+ T-cells that ranged 1.8- to 2.6-fold higher over baseline against an A(H3N2) strain for the
308 three enhanced vaccines; and corresponding fold-rises against a B/Victoria lineage strain that
309 ranged from 1.38 to 2.16.¹⁸ In contrast, in the present phase 3 trial, qNIV with Matrix-M achieved
310 a 5.1- and 7.9-fold rise increase in Day 7 post-vaccination IFN- γ -producing CD4+ T-cell
311 responses against A(H3N2) and B-Victoria lineage strains, respectively (Table S2). Notably, and
312 in contrast to IIV4, qNIV with Matrix-M was able to activate influenza-specific polyfunctional

313 cellular immune responses even among participants with the lowest levels of baseline T-cell
314 reactivity—a crucial feature for developing protective immune responses in those with a greater
315 degree of immunosenescence due to advanced age, physiological frailty, or multi-morbidity.¹⁷

316 Finally, the use of recombinant technology is important not only for producing a wild-type HA
317 sequence-matched qNIV, but also for developing wild-type reagent based HAI assays to
318 measure immunogenicity more accurately. Recent studies have elucidated the untoward effect
319 of vaccine virus propagation in embryonated hen eggs on the emergence of deleterious
320 antigenic site mutations on HAs of vaccine virus strains, particularly A(H3N2), which not only
321 contribute to reduced VE due to apparent “antigenic mismatch” between circulating and egg-
322 derived vaccine strains, but also call into question the meaningfulness of traditional HAI
323 antibody measurements assayed with egg-propagated reagents derived in the same
324 fashion.^{8,12,13,15,16} Our phase 2 and 3 data further underscore this problem: in the phase 3 trial,
325 we noted a substantial improvement in the relative HAI antibody responses comparing qNIV and
326 IIV4 when assayed with egg-based reagents (3-23% relative improvement) versus when
327 assayed with wild-type reagents (24-66% relative improvement) (Table 3), and in phase 2 trial,
328 we could demonstrate orthogonal support for the discrepant egg-based versus wild-type HAI
329 observations by comparing the performance of microneutralization antibody assays employing
330 egg-derived versus wild-type virus reagents (Figure S10).⁴⁰

331 Our findings indicate that the improved humoral and cellular immune responses elicited by
332 qNIV—a consequence of the nanoparticle antigen structure, the Matrix-M adjuvant, and
333 recombinant technology—hold potential to address critical gaps in currently licensed influenza
334 vaccines.

335

336 **CONTRIBUTORS**

337 All co-authors contributed substantially to the conception and development of the trial. VS, LF,
338 GG, CK, and IC contributed substantially to the design and interpretation of data, and
339 manuscript review. IC provided statistical expertise, developed the statistical analysis plan, and
340 source tables, listings, and figures. RC and NW provided statistical programming. JP, MZ, BZ
341 and SC developed and conducted HAI assays. BZ conducted nonclinical assays to support
342 scientific development of trial design. HZ developed and conducted CMI assays. GS, NP, MM
343 provided scientific expertise for the development of the study and manuscript concepts. SA
344 drafted the manuscript and developed manuscript tables and figures. JF, ML, PP provided
345 clinical operations, regulatory, and pharmacovigilance support. XP provided medical writing
346 support for trial protocol and amendments.

347 **DECLARATION OF INTERESTS**

348 All co-authors are current or former employees of Novavax, the sponsor of the trial.

349 **ACKNOWLEDGMENTS**

350 We thank the trial participants, the investigators from the clinical trial sites, members of the
351 sponsor's and the contract research organization (CRO)'s team, and the Clinical Immunology
352 laboratory for their contributions to the trial. Editorial assistance on the preparation of this
353 manuscript was provided by Phase Five Communications, supported by Novavax, Inc.

354

355

356 **REFERENCES**

- 357 1. CDC. Vaccination Coverage among Adults in the United States, National Health
358 Interview Survey, 2017. [https://www.cdc.gov/vaccines/imz-](https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html)
359 [managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html](https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html) (accessed May 02, 2020
360 2020).
- 361 2. Reed C, Chaves SS, Daily Kirley P, et al. Estimating Influenza Disease Burden from
362 Population-Based Surveillance Data in the United States. *PLOS ONE* 2015; **10**(3): e0118369.
- 363 3. Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention
364 and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee
365 on Immunization Practices — United States, 2019–20 Influenza Season. *MMWR*
366 *Recommendations and Reports* 2019; **68**(3): 1-21.
- 367 4. CDC) UCfDCaPU. Past Seasons Vaccine Effectiveness Estimates.
368 <https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html> (accessed July 26, 2020.
- 369 5. Flannery B, Kondor RJG, Chung JR, et al. Spread of Antigenically Drifted Influenza
370 A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season.
371 *J Infect Dis* 2020; **221**(1): 8-15.
- 372 6. Rolfes MA, Flannery B, Chung JR, et al. Effects of Influenza Vaccination in the United
373 States During the 2017-2018 Influenza Season. *Clin Infect Dis* 2019; **69**(11): 1845-53.
- 374 7. Belongia EA, McLean HQ. Influenza Vaccine Effectiveness: Defining the H3N2
375 Problem. *Clin Infect Dis* 2019; **69**(10): 1817-23.
- 376 8. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing Seasonal Influenza - The Need
377 for a Universal Influenza Vaccine. *N Engl J Med* 2018; **378**(1): 7-9.
- 378 9. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of
379 mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza
380 type or subtype, age, cause of death, and risk status. *Influenza and Other Respiratory Viruses*
381 2014; **8**(5): 507-15.
- 382 10. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of
383 hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk
384 status. *BMC Public Health* 2017; **17**(1).
- 385 11. Paules CI, Fauci AS. Influenza Vaccines: Good, but We Can Do Better. *The Journal of*
386 *Infectious Diseases* 2019; **219**(Supplement_1): S1-S4.
- 387 12. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a
388 glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. *Proc*
389 *Natl Acad Sci U S A* 2017; **114**(47): 12578-83.
- 390 13. Gouma S, Zost SJ, Parkhouse K, et al. Comparison of human H3N2 antibody responses
391 elicited by egg-based, cell-based, and recombinant protein-based influenza vaccines during the
392 2017-2018 season. *Clin Infect Dis* 2019.
- 393 14. Paules CI, Fauci AS. Influenza Vaccines: Good, but We Can Do Better. *J Infect Dis*
394 2019; **219**(Suppl_1): S1-S4.
- 395 15. Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness
396 of the seasonal influenza H3N2 vaccine. *PLOS Pathogens* 2017; **13**(10): e1006682.
- 397 16. Levine MZ, Martin ET, Petrie JG, et al. Antibodies Against Egg- and Cell-Grown
398 Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017–2018 Influenza Season. *The*
399 *Journal of Infectious Diseases* 2019; **219**(12): 1904-12.

- 400 17. McElhaney JE, Andrew MK, Haynes L, Kuchel GA, McNeil SA, Pawelec G. Influenza
401 Vaccination: Accelerating the Process for New Vaccine Development in Older Adults.
402 *Interdiscip Top Gerontol Geriatr* 2020; **43**: 98-112.
- 403 18. Cowling BJ, Perera R, Valkenburg SA, et al. Comparative Immunogenicity of Several
404 Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. *Clin*
405 *Infect Dis* 2019.
- 406 19. Kumar A, McElhaney JE, Walrond L, et al. Cellular immune responses of older adults to
407 four influenza vaccines: Results of a randomized, controlled comparison. *Human Vaccines &*
408 *Immunotherapeutics* 2017; **13**(9): 2048-57.
- 409 20. McElhaney JE, Zhou X, Talbot HK, et al. The unmet need in the elderly: how
410 immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the
411 development of more effective influenza vaccines. *Vaccine* 2012; **30**(12): 2060-7.
- 412 21. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-
413 dose influenza vaccine in older adults. *N Engl J Med* 2014; **371**(7): 635-45.
- 414 22. Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of
415 Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults \geq 50
416 years of age. *Vaccine* 2015; **33**(48): 6622-8.
- 417 23. Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of
418 an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
419 *Vaccine* 2014; **32**(39): 5027-34.
- 420 24. Diazgranados CA, Dunning AJ, Kimmel M, et al. Efficacy of High-Dose versus
421 Standard-Dose Influenza Vaccine in Older Adults. *New England Journal of Medicine* 2014;
422 **371**(7): 635-45.
- 423 25. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of Recombinant Influenza Vaccine in
424 Adults 50 Years of Age or Older. *N Engl J Med* 2017; **376**(25): 2427-36.
- 425 26. Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, Group QS. Safety and
426 immunogenicity of high-dose quadrivalent influenza vaccine in adults \geq 65 years of age: A
427 phase 3 randomized clinical trial. *Vaccine* 2019; **37**(39): 5825-34.
- 428 27. Tsang P, Gorse GJ, Strout CB, et al. Immunogenicity and safety of Fluzone(®)
429 intradermal and high-dose influenza vaccines in older adults \geq 65 years of age: a randomized,
430 controlled, phase II trial. *Vaccine* 2014; **32**(21): 2507-17.
- 431 28. Essink B, Fierro C, Rosen J, et al. Immunogenicity and safety of MF59-adjuvanted
432 quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent
433 influenza vaccines in older adults. *Vaccine* 2020; **38**(2): 242-50.
- 434 29. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, Vanwormer JJ.
435 Waning vaccine protection against influenza A (H3N2) illness in children and older adults
436 during a single season. *Vaccine* 2015; **33**(1): 246-51.
- 437 30. Van Buynder PG, Konrad S, Van Buynder JL, et al. The comparative effectiveness of
438 adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
439 *Vaccine* 2013; **31**(51): 6122-8.
- 440 31. Mannino S, Villa M, Apolone G, et al. Effectiveness of Adjuvanted Influenza
441 Vaccination in Elderly Subjects in Northern Italy. *American Journal of Epidemiology* 2012;
442 **176**(6): 527-33.
- 443 32. Tsai TF. Flud(R)-MF59(R)-Adjuvanted Influenza Vaccine in Older Adults. *Infect*
444 *Chemother* 2013; **45**(2): 159-74.


- 445 33. Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, Post-Marketing Safety
446 Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(R) and VANTAFLU(R) in
447 South Korean Subjects Aged \geq 65 Years. *Infect Chemother* 2018; **50**(4): 301-10.
- 448 34. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and
449 immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza
450 vaccine in non-elderly adults. *Vaccine* 2003; **21**(27-30): 4234-7.
- 451 35. Izurieta HS, Chillarige Y, Kelman J, et al. Relative Effectiveness of Cell-Cultured and
452 Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017–2018. *The*
453 *Journal of Infectious Diseases* 2019; **220**(8): 1255-64.
- 454 36. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the
455 safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-
456 expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64
457 years of age. *Vaccine* 2011; **29**(12): 2272-8.
- 458 37. Smith G, Liu Y, Flyer D, et al. Novel hemagglutinin nanoparticle influenza vaccine with
459 Matrix-M adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in
460 ferrets against homologous and drifted A(H3N2) subtypes. *Vaccine* 2017; **35**(40): 5366-72.
- 461 38. Portnoff AD, Patel N, Massare MJ, et al. Influenza Hemagglutinin Nanoparticle Vaccine
462 Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA.
463 *Vaccines* 2020; **8**(1): 99.
- 464 39. Shinde V, Fries L, Wu Y, et al. Improved Titers against Influenza Drift Variants with a
465 Nanoparticle Vaccine. *N Engl J Med* 2018; **378**(24): 2346-8.
- 466 40. Shinde V. Induction of Cross-reactive Hemagglutination Inhibiting Antibody and
467 Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin
468 Nanoparticle Influenza Vaccine *medRxiv* 2020.
- 469 41. Sanofi Pasteur. Fluzone® High-Dose (Influenza Vaccine) [package insert]. U.S. Food
470 and Drug Administration. <https://www.fda.gov/media/119870/download> (accessed June 2, 2020).
- 471 42. Seqirus. FLUAD® (Influenza Vaccine, Adjuvanted) [package insert]. U.S. Food and
472 Drug Administration. <https://www.fda.gov/media/94583/download> (accessed June 2, 2020).
- 473 43. Bengtsson KL, Karlsson KH, Magnusson SE, Reimer JM, Stertman L. Matrix-M
474 adjuvant: enhancing immune responses by 'setting the stage' for the antigen. *Expert Rev Vaccines*
475 2013; **12**(8): 821-3.
- 476 44. Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular
477 and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle
478 vaccine in mice. *Vaccine* 2016; **34**(16): 1927-35.
- 479 45. Cox RJ, Pedersen G, Madhun AS, et al. Evaluation of a virosomal H5N1 vaccine
480 formulated with Matrix M adjuvant in a phase I clinical trial. *Vaccine* 2011; **29**(45): 8049-59.
- 481 46. Magnusson SE, Altenburg AF, Bengtsson KL, et al. Matrix-M adjuvant enhances
482 immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in
483 mice. *Immunol Res* 2018; **66**(2): 224-33.
- 484 47. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune
485 enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to
486 an influenza vaccine in mice. *Vaccine* 2013; **31**(13): 1725-33.
- 487 48. Reimer JM, Karlsson KH, Lovgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L.
488 Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells
489 in absence of antigen. *PLoS One* 2012; **7**(7): e41451.

- 490 49. Fries L, Cho I, Krähling V, et al. Randomized, Blinded, Dose-Ranging Trial of an Ebola
 491 Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. *The*
 492 *Journal of Infectious Diseases* 2019.
 493 50. Fries LF, Smith GE, Glenn GM. A Recombinant Viruslike Particle Influenza A (H7N9)
 494 Vaccine. *New England Journal of Medicine* 2013; **369**(26): 2564-6.

495

496 **[Tables and Figures]**

497 **Figure 1: Trial Profile**



498

499 Abbreviations: AE, adverse event; N, number of participants in trial; n, number of participants in specified
 500 category; ITT, intent-to-treat; PP, per protocol.

501 Participant disposition through trial Day 28 is shown. Blinded 1-year safety follow-up is ongoing.

502 The PP population was the primary population for immunogenicity analysis and included randomized
 503 participants who received the assigned dose of the test article according to the protocol, had HAI serology
 504 results at Day 0 and Day 28, and had no major protocol deviations).

505 The ITT population included all participants in the safety population that provided any HAI serology data.

506 The safety population included all trial participants that provided consent, were randomized, and received
507 the test article. The safety population was used for all safety analyses; and was analyzed as actually
508 treated.

509 **Table 1: Demographic and key baseline characteristics of trial participants in the safety**
510 **population**

	qNIV N=1333	IIV4 N=1319
Age		
Mean (SD), years	72.5 (5.7)	72.5 (5.7)
Median, years	72.0	71.0
Sex		
Male, n (%)	541 (40.6)	474 (35.9)
Female, n (%)	792 (59.4)	845 (64.1)
Race/Ethnicity		
White, n (%)	1208 (90.6)	1200 (91.0)
Black/African American, n (%)	105 (7.9)	103 (7.8)
All other, n (%)	20 (1.5)	16 (1.2)
Received flu vaccine in 2018-2019, n (%)	1117 (83.8)	1102 (83.5)
Received any flu vaccine in past 3 years, n (%)	1210 (90.8)	1200 (91.0)

511 Abbreviations: IIV4, quadrivalent inactivated influenza vaccine; N, number of participants in treatment
512 group; qNIV, quadrivalent nanoparticle influenza vaccine; SD, standard deviation.

513 The safety population included all trial participants who provided consent, were randomized, and received
514 the test article. The safety population was used for all safety analyses and was analyzed as actually
515 treated.

516

517

518 **Table 2: Summary of adverse events among trial participants through Day 28**

	qNIV N=1333	IIV4 N=1319
	Counts (%) of participants with events (95% CI)	
Any treatment-emergent adverse event (TEAE)	659 (49.4)	551 (41.8)
	(46.7-52.2)	(39.1-44.5)
Any solicited AEs	551 (41.3)	420 (31.8)
	(38.7-44.0)	(29.3- 34.4)
Severe solicited AEs ^a	21 (1.6)	13 (1.0)
	(1.0- 2.4)	(0.5- 1.7)
Solicited local AEs	372 (27.9)	243 (18.4)
	(25.5-30.4)	(16.4-20.6)
Severe solicited local AEs	8 (0.6)	2 (0.2)
	(0.3-1.2)	(0.0-0.5)
Solicited systemic AEs	369 (27.7)	292 (22.1)
	(25.3-30.2)	(19.9-24.5)
Severe solicited systemic AEs	15 (1.1)	11 (0.8)
	(0.6- 1.8)	(0.4-1.5)
Unsolicited AEs	248 (18.6)	241 (18.3)
	(16.5-20.8)	(16.2-20.5)
Related unsolicited AEs	62 (4.7)	34 (2.6)
	(3.6-5.9)	(1.8-3.6)
Severe unsolicited AEs	23 (1.7)	12 (0.9)
	(1.1-2.6)	(0.5- 1.6)
Severe and related unsolicited AEs	10 (0.8)	2 (0.2)
	(0.4-1.4)	(0.0-0.5)
Serious AEs	11 (0.8)	5 (0.4)

	(0·4-1·5)	(0·1-0·9)
Related serious AEs	0 (0·0)	0 (0·0)
	(0·0-0·3)	(0·0-0·3)
Significant new medical conditions	7 (0·5)	10 (0·8)
	(0·2-1·1)	(0·4-1·4)
Medically attended unsolicited AEs	99 (7·4)	104 (7·9)
	(6·1-9·0)	(6·5-9·5)

519 Abbreviations: AE, adverse event; CI, confidence interval; IIV4, quadrivalent inactivated influenza
520 vaccine; qNIV, quadrivalent nanoparticle influenza vaccine; TEAE, treatment-emergent adverse event.
521 An AE was considered treatment-emergent if it began on or after trial Day 0 vaccination.
522 Participants with multiple events within a category were counted only once, using the event with the
523 greatest severity and/or relationship (Possible, Probably, Definite) as applicable. For the total number of
524 TEAEs for each respective category, counts were limited to those events that fulfilled the AE category.
525 ^aSolicited AEs were reported by participants (via diary or spontaneously) and had a recorded start date
526 within the 7-day post-vaccination window (ie, from trial Day 0 through Day 6).
527 Safety follow-up from Day 28 through Day 364 after immunization is ongoing and remains blinded. To
528 protect the integrity of safety data collection, data reported here have been provided to the sponsor's
529 clinical and regulatory personnel at the treatment group level only.

530 **Table 3: Summary of egg-virus or wild-type VLP-based Day 28 HAI GMTs, GMT ratios, SCR, and SCR difference for vaccine-**
 531 **homologous strains**

Virus Characteristics	Influenza Virus Strain							
	A/Brisbane		A/Kansas		B/Maryland		B/Phuket	
	Subtype or Lineage		H3N2		B/Victoria		B/Yamagata	
	Clade/Subclade		3C.3a		V1A-2DEL		3	
Hemisphere/Season	NH/2019-20		NH/2019-20		NH/2019-20		NH/2019-20	
Assay	HAI (Egg)	HAI (wtVLP)	HAI (Egg)	HAI (wtVLP)	HAI (Egg)	HAI (wtVLP)	HAI (Egg)	HAI (wtVLP)
Treatment qNIV (N=1280) Variable								
Day 0 GMT	26.2	31.7	55.1	27.3	70.7	29.8	69.1	45.8
(95% CI)	(25.0-27.4)	(30.0-33.5)	(53.5-56.8)	(26.1-28.6)	(68.0-73.5)	(28.5-31.1)	(66.0-72.3)	(44.0-47.7)
Day 28 GMT	49.3	76.6	151.5	153.6	110.7	62.8	168.5	118.3
(95% CI)	(46.7-51.9)	(72.4-81.1)	(143.3-160.2)	(143.9-163.9)	(106.1-115.6)	(59.8-66.0)	(160.2-177.2)	(113.0-123.8)
Day 28 GMTR _(post/pre)	1.9	2.4	2.7	5.6	1.6	2.1	2.4	2.6
(95% CI)	(1.8-2.0)	(2.3-2.5)	(2.6-2.9)	(5.3-6.0)	(1.5-1.6)	(2.0-2.2)	(2.3-2.5)	(2.5-2.7)
p-value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Day 28 SCR	282 (22.0)	419 (32.7)	535 (41.8)	894 (69.8)	143 (11.2)	321 (25.1)	401 (31.3)	453 (35.4)
(95% CI)	(19.8-24.4)	(30.2-35.4)	(39.1-44.6)	(67.2-72.3)	(9.5-13.0)	(22.7-27.5)	(28.8-33.9)	(32.8-38.1)
Day 28 SPR	884 (69.1)	1055 (82.4)	1265 (98.8)	1182 (92.3)	1269 (99.1)	1039 (81.2)	1267 (99.0)	1240 (96.9)
(95% CI)	(66.4-71.6)	(80.2-84.5)	(98.1-99.3)	(90.7-93.7)	(98.5-99.6)	(78.9-83.3)	(98.3-99.5)	(95.8-97.8)
IIV4 (N=1286)								
Day 0 GMT	26.0	32.4	54.7	26.5	69.8	29.5	66.5	44.3
(95% CI)	(24.9-27.1)	(30.7-34.2)	(53.1-56.3)	(25.4-27.7)	(67.2-72.5)	(28.3-30.8)	(63.6-69.6)	(42.7-46.1)
Day 28 GMT	45.0	62.7	126.8	90.7	106.3	47.2	133.9	78.4
(95% CI)	(42.7-47.3)	(59.2-66.4)	(120.3-133.6)	(84.9-96.9)	(102.3-110.6)	(45.2-49.4)	(127.7-140.5)	(75.1-81.9)
Day 28 GMTR _(post/pre)	1.7	1.9	2.3	3.4	1.5	1.6	2.0	1.8
(95% CI)	(1.7-1.8)	(1.8-2.0)	(2.2-2.4)	(3.2-3.6)	(1.5-1.6)	(1.5-1.7)	(1.9-2.1)	(1.7-1.8)
p-value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

Day 28 SCR (95% CI)	219 (17.0) (15.0-19.2)	275 (21.4) (19.2-23.7)	443 (34.4) (31.8-37.1)	636 (49.5) (46.7-52.2)	137 (10.7) (9.0-12.5)	173 (13.5) (11.6-15.4)	294 (22.9) (20.6-25.3)	228 (17.7) (15.7-19.9)
Day 28 SPR (95% CI)	830 (64.5) (61.9-67.2)	985 (76.6) (74.2-78.9)	1264 (98.3) (97.4-98.9)	1045 (81.3) (79.0-83.4)	1269 (98.7) (97.9-99.2)	933 (72.6) (70.0-75.0)	1254 (97.5) (96.5-98.3)	1174 (91.3) (89.6-92.8)

Day 28 Baseline-adjusted GMTR_(qNIV/IIV4) (95% CI) p-value	1.09 (1.03-1.15) 0.003	1.24 (1.17-1.32) <0.001	1.19 (1.11-1.27) <0.001	1.66 (1.53-1.79) <0.001	1.03 (0.99-1.07) 0.146	1.32 (1.26-1.39) <0.001	1.23 (1.16-1.29) <0.001	1.47 (1.40-1.55) <0.001
---	------------------------------	-------------------------------	-------------------------------	-------------------------------	------------------------------	-------------------------------	-------------------------------	-------------------------------

Day 28 Absolute SCR difference (qNIV-IIV4) (95% CI) p-value	5.0 (1.9-8.1) 0.002	11.4 (7.9-14.7) <0.001	7.3 (3.6-11.1) <0.001	20.4 (16.6-24.1) <0.001	0.5 (-1.9-2.9) 0.720	11.6 (8.6-14.6) <0.001	8.5 (5.0-11.9) <0.001	17.7 (14.3-21.0) <0.001
--	---------------------------	------------------------------	-----------------------------	-------------------------------	----------------------------	------------------------------	-----------------------------	-------------------------------

532 Abbreviations: CI, confidence interval; GMTR_(post/pre), geometric mean titer ratio; GMTR_(qNIV/IIV4), ratio of GMTs between qNIV and IIV4; GMT,
533 geometric mean titer; HAI, hemagglutination inhibition; IIV4, quadrivalent inactivated influenza vaccine; NA, not applicable; qNIV, quadrivalent
534 nanoparticle influenza vaccine; SCR, seroconversion rate; SPR, seroprotection rate; VLP, virus-like particle; wt, wild-type.

535 Full strain names: A/Brisbane/02/2018 (H1N1) pdm09; A/Kansas/14/2017 (H3N2); B/Maryland/15/2016 (Victoria lineage); B/Phuket/3073/2013
536 (Yamagata lineage).

537 GMT was defined as the antilog of the mean of the log-transformed titer values for a given treatment group and time-point. Individual antibody
538 values recorded as below the lower limit of quantitation (LLoQ) were set to half LLoQ.

539 SCR was defined as percentage of participants with either a baseline HAI titer <1:10 and a post-vaccination titer ≥1:40, or a baseline HAI titer
540 ≥1:10 and a four-fold increase in post-vaccination HAI titer relative to baseline. Percentages were based on the number of participants with non-

541 missing HAI titer values in the per-protocol (PP) population who received that treatment. Clopper-Pearson method was applied to calculate the
542 proportion CI. Individual antibody values recorded as below the LLoQ were set to half LLoQ.

543 SPR was defined as percentage of participants with an HAI titer $\geq 1:40$. Percentages were based on the number of participants with non-missing
544 HAI titer values in the PP population who received that treatment. Clopper-Pearson method was applied to calculate the proportion CI. Individual
545 antibody values recorded as below the LLoQ were set to half LLoQ.

546 $GMTR_{(post/pre)}$ was defined as the ratio of the two geometric mean titers within treatment group at 2 different timepoints, ie, between post-
547 vaccination (Day 28) and pre-vaccination (Day 0). 95% CI and p-value were obtained by paired t test of $GMR=1$. Individual antibody values
548 recorded as below the LLoQ were set to half LLoQ.

549 $GMTR_{(qNIV/IIV4)}$ was defined as the ratio of 2 GMTs for a comparison of two specified treatment groups (qNIV and IIV4) at Day 28. A mixed-effects
550 model with treatment group and baseline HAI antibody titers as covariates was performed. The ratios of geometric least square (LS) means and
551 95% CIs for the ratio were calculated by back transforming the mean differences and 95% confidence limits for the differences of log (base 10)
552 transformed total HAI antibody titers between two specified treatment groups. Individual antibody values recorded as below the LLoQ were set to
553 half LLoQ.

554 Two-sided 95% CIs for absolute SCR differences were constructed based on Newcombe hybrid score. Chi-Square p-value was derived for testing
555 the equality of SCRs between two groups with continuity adjustment for small sample size. Individual antibody values recorded as below the LLoQ
556 were set to half LLoQ.

557

558 **Table 4: Summary of wild-type VLP-based Day 28 HAI GMTs, GMT ratios, SCR, and SCR differences for drifted A(H3N2)**
 559 **strains**

Virus Characteristics	Influenza Virus Strain						
	A/California	A/Cardiff	A/Netherlands	A/South Australia	A/Idaho	A/Tokyo	B/Washington
	H3N2	H3N2	H3N2	H3N2	H3N2	H3N2	B/Victoria
	3C.2a1b+131K	3C.2a1b+135K	3c.3a	3C.2a1b+131K	3c.3a	3C.2a2	V1A-3DEL
Hemisphere/Season	NA	NA	NA	SH/2020	NA	NA	SH/2020
Treatment							
qNIV (N=1280)							
Variable							
Day 0 GMT	44.5	27.0	39.4	39.3	53.6	32.2	48.7
(95% CI)	(42.4-46.7)	(26.0-28.1)	(37.7-41.2)	(37.5-41.2)	(51.6-55.8)	(31.0-33.4)	(47.0-50.5)
Day 28 GMT	115.0	63.9	102.3	98.1	202.5	78.0	88.2
(95% CI)	(108.0-122.4)	(60.5-67.6)	(96.5-108.5)	(92.1-104.4)	(191.2-214.4)	(73.8-82.5)	(84.7-91.8)
Day 28 GMTR _(post/pre)	2.6	2.4	2.6	2.5	3.8	2.4	1.8
(95% CI)	(2.5-2.7)	(2.3-2.5)	(2.5-2.7)	(2.4-2.6)	(3.6-4.0)	(2.3-2.5)	(1.8-1.9)
p-value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Day 28 SCR	475 (37.1)	419 (32.7)	492 (38.4)	440 (34.4)	735 (57.5)	444 (34.7)	226 (17.7)
(95% CI)	(34.5-39.8)	(30.2-35.4)	(35.8-41.2)	(31.8-37.0)	(54.7-60.2)	(32.1-37.4)	(15.6-19.9)
Day 28 SPR	1140 (89.1)	985 (77.0)	1131 (88.4)	1111 (86.8)	1259 (98.4)	1078 (84.2)	1233 (96.4)
(95% CI)	(87.2-90.7)	(74.5-79.2)	(86.5-90.1)	(84.8-88.6)	(97.6-99.0)	(82.1-86.2)	(95.2-97.4)
IIV4 (N=1286)							
Day 0 GMT	44.0	25.7	39.6	38.3	52.9	31.2	48.4
(95% CI)	(42.0-46.0)	(24.7-26.6)	(38.0-41.3)	(36.6-40.1)	(50.9-55.0)	(30.1-32.3)	(46.8-50.1)
Day 28 GMT	80.6	45.4	74.7	70.4	136.8	54.5	71.4
(95% CI)	(75.9-85.6)	(43.1-47.8)	(70.6-79.0)	(66.3-74.7)	(129.5-144.6)	(51.7-57.4)	(69.0-74.0)
Day 28 GMTR _(post/pre)	1.8	1.8	1.9	1.8	2.6	1.7	1.5
(95% CI)	(1.8-1.9)	(1.7-1.8)	(1.8-2.0)	(1.8-1.9)	(2.5-2.7)	(1.7-1.8)	(1.4-1.5)
p-value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

Day 28 SCR (95% CI)	264 (20.5) (18.4-22.8)	239 (18.6) (16.5-20.8)	278 (21.7) (19.4-24.0)	252 (19.6) (17.5-21.9)	497 (38.7) (36.1-41.5)	231 (18.0) (15.9-20.2)	124 (9.7) (8.1-11.4)
Day 28 SPR (95% CI)	1056 (82.1) (79.9-84.2)	835 (64.9) (62.3-67.5)	1066 (83.0) (80.9-85.0)	1013 (78.9) (76.6-81.1)	1249 (97.3) (96.3-98.2)	947 (73.8) (71.3-76.1)	1211 (94.4) (93.0-95.6)

Day 28 Baseline-adjusted GMTR_(qNIV/IIV4) (95% CI) p-value	1.41 (1.33-1.50) <0.001	1.34 (1.27-1.43) <0.001	1.38 (1.30-1.46) <0.001	1.36 (1.28-1.44) <0.001	1.46 (1.37-1.56) <0.001	1.39 (1.31-1.48) <0.001	1.23 (1.18-1.28) <0.001
---	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------

Day 28 Absolute SCR difference (qNIV-IIV4) (95% CI) p-value	16.6 (13.1-20.0) <0.001	14.1 (10.8-17.5) <0.001	16.8 (13.3-20.2) <0.001	14.7 (11.3-18.1) <0.001	18.8 (14.9-22.5) <0.001	16.7 (13.3-20.0) <0.001	8.0 (5.4-10.7) <0.001
--	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-----------------------------

560 Abbreviations: CI, confidence interval; GMTR_(post/pre), geometric mean titer ratio; GMTR_(qNIV/IIV4), ratio of GMTs between qNIV and IIV4; GMT,
561 geometric mean titer; HAI, hemagglutination inhibition; IIV4, quadrivalent inactivated influenza vaccine; NA, not applicable; qNIV, quadrivalent
562 nanoparticle influenza vaccine; SCR, seroconversion rate; SPR, seroprotection rate; VLP, virus-like particle; wt, wild-type.

563 Full strain names: A/California/94/2019; A/Cardiff/508/2019; A/Netherlands/1268/2019; A/South Australia/34/2019; A/Idaho/13/2018;
564 A/Tokyo/EH1801/2018; B/Washington/02/2019.

565 GMT was defined as the antilog of the mean of the log-transformed titer values for a given treatment group and time-point. Individual antibody
566 values recorded as below the lower limit of quantitation (LLoQ) were set to half LLoQ.

567 SCR was defined as percentage of participants with either a baseline HAI titer <1:10 and a post-vaccination titer ≥1:40, or a baseline HAI titer
568 ≥1:10 and a four-fold increase in post-vaccination HAI titer relative to baseline. Percentages were based on the number of participants with non-
569 missing HAI titer values in the per-protocol (PP) population who received that treatment. Clopper-Pearson method was applied to calculate the
570 proportion CI. Individual antibody values recorded as below the LLoQ were set to half LLoQ.

571 SPR was defined as percentage of participants with an HAI titer $\geq 1:40$. Percentages were based on the number of participants with non-missing
572 HAI titer values in the PP population who received that treatment. Clopper-Pearson method was applied to calculate the proportion CI. Individual
573 antibody values recorded as below the LLoQ were set to half LLoQ.

574 $GMTR_{(post/pre)}$ was defined as the ratio of the two geometric mean titers within treatment group at 2 different timepoints, ie, between post-
575 vaccination (Day 28) and pre-vaccination (Day 0). 95% CI and p-value were obtained by paired t test of GMR=1. Individual antibody values
576 recorded as below the LLoQ were set to half LLoQ.

577 $GMTR_{(qNIV/IIV4)}$ was defined as the ratio of 2 GMTs for a comparison of two specified treatment groups (qNIV and IIV4) at Day 28. A mixed-effects
578 model with treatment group and baseline HAI antibody titers as covariates was performed. The ratios of geometric least square (LS) means and
579 95% CIs for the ratio were calculated by back transforming the mean differences and 95% confidence limits for the differences of log (base 10)
580 transformed total HAI antibody titers between two specified treatment groups. Individual antibody values recorded as below the LLoQ were set to
581 half LLoQ.

582 Two-sided 95% CIs for absolute SCR differences were constructed based on Newcombe hybrid score. Chi-Square p-value was derived for testing
583 the equality of SCRs between two groups with continuity adjustment for small sample size. Individual antibody values recorded as below the LLoQ
584 were set to half LLoQ.

585


586 **Figure 2a: Box plot for log₁₀ scale counts of at least double cytokine- expressing CD4 + effector T-cells against A/Kansas.**

587 **Figure 2b: RCD plot for proportion of at least double cytokine-expressing CD4 + effector T-cells against A/Kansas.**

588 **Figure 2c: Geometric mean fold-rise at Day 7 with qNIV and IIV4 across polyfunctional phenotypes for effector and total**
589 **CD4+T-cells.**

590

a.



591

592 Cell-mediated immune (CMI) responses were measured by intracellular cytokine staining (ICCS). Counts of peripheral blood CD4+

593 T-cells expressing IL-2, IFN- γ , TNF- α and/or CD40L+ cytokines were measured following in vitro re-stimulation with A/Kansas.

594 Responses were evaluated using peripheral blood mononuclear cells (PBMCs) obtained from a subgroup of participants on Day 0


595 (pre-vaccination) and Day 7. The box plots represent the interquartile range (± 3 standard deviations); the solid horizontal black line

596 represents the median and the number indicates the median count of CD4+ effector T-cells against A/Kansas, expressing at least
597 any two of: IFN- γ , TNF- α , IL-2, or CD40L+; and the open diamond represents the mean.

598

599

b.



600

601

602

603


604

605

606

607

c.



608
609

610 IFN- γ +, CD4+ effector or total T-cells expressing IFN- γ ; double cytokine+, CD4+ effector or total T-cells expressing any two of: IFN- γ ,
611 TNF- α , IL-2, or CD40L+; triple cytokine+, CD4+ effector or total T-cells expressing any three of: IFN- γ , TNF- α , IL-2, or CD40L+;
612 quadruple cytokine+, CD4+ effector or total T-cells expressing IFN- γ , TNF- α , IL-2, and CD40L+.

613 Cell-mediated immune (CMI) response endpoints were performed on a subset of approximately 140 participants from several pre-
614 designated clinical sites. For CD4+ effector T-cells, the lower limit of quantitation (LLoQ) was set as 70. If cytokine was <70, log₁₀
615 scale of cytokines counts was recorded as log₁₀ scale half LLoQ, which is 35. For CD4 + total T-cells, LLoQ was set as 40. If cytokine
616 was <40, log₁₀ scale of cytokines counts was recorded as log₁₀ scale half LLoQ, which is 20.

617 For IFN- γ , LLoQ was set as 110 for effector CD4+ T-cells, and 30 for total CD4+ T-cells. Thus, if cytokines count was <LLoQ, log₁₀
618 scale of cytokine count was recorded as log₁₀ scale half LLoQ, which is 55 and 15, respectively.

619 $GMFR_{(post/pre)}$ was defined as the ratio of two GMCs within treatment group at two different time-points (ie, between Day 7 and Day 0).
620 95% CI and p-value were obtained by paired t test of $GMR=1$. Note: GMC was defined as the antilog of the mean of the log-
621 transformed counts for a given treatment group and time-point.